Carvedilol Prevents Impairment of the Counterregulatory Response in Recurrently Hypoglycaemic Diabetic Rats

Overview

Journal Endocrinol Diabetes Metab

Specialty Endocrinology

Date 2021 Apr 15

PMID 33855225

Citations 4

Authors

Rawad Farhat

Eliane de Santana-Van Vliet

Gong Su

Levi Neely

Thea Benally

Owen Chan

Affiliations

Soon will be listed here.

Abstract

Aim: It has been suggested that repeated activation of the adrenergic system during antecedent episodes of hypoglycaemia contributes to the development of counterregulatory failure. We previously reported that treatment with carvedilol, a non-specific β-blocker, prevented the development of counterregulatory failure and improved hypoglycaemia awareness in recurrently hypoglycaemic non-diabetic rats. The current study investigated whether carvedilol has similar benefits in diabetic rats.

Methods: Recurrently hypoglycaemic streptozotocin-diabetic rats (STZ+RH) were treated with carvedilol for one week prior to undergoing a hypoglycaemic clamp. Hypoglycaemia awareness was evaluated in streptozotocin-diabetic rats made hypoglycaemia unaware using repeated injections of 2-deoxyglucose.

Results: Compared to hypoglycaemia-naïve STZ-diabetic controls, exogenous glucose requirements were more than doubled in the STZ+RH animals and this was associated with a 49% reduction in the epinephrine response to hypoglycaemia. Treating STZ+RH animals with carvedilol improved the epinephrine response to hypoglycaemia. Of note, neither recurrent hypoglycaemia nor carvedilol treatment affected the glucagon response in diabetic animals. Additionally, carvedilol treatment improved the feeding response to insulin-induced hypoglycaemia in diabetic animals made 'hypoglycaemia unaware' using repeated injections of 2-deoxyglucose, suggesting the treatment improved awareness of hypoglycaemia as well.

Conclusion: Our data suggest that carvedilol may be useful in preventing impairments of the sympathoadrenal response and the development of hypoglycaemia unawareness during recurring episodes of hypoglycaemia in diabetic animals.

Citing Articles

Glucagon-like peptide-1 and impaired counterregulatory responses to hypoglycemia in type 1 diabetes.

Rocha G, de Melo F World J Diabetes. 2025; 16(2):99928.

PMID: 39959274 PMC: 11718485. DOI: 10.4239/wjd.v16.i2.99928.

Role of the Adrenal Medulla in Hypoglycaemia-Associated Autonomic Failure-A Diabetic Perspective.

Senthilkumaran M, Koch C, Herselman M, Bobrovskaya L Metabolites. 2024; 14(2).

PMID: 38392992 PMC: 10890365. DOI: 10.3390/metabo14020100.

Experimental pharmacological approaches to reverse impaired awareness of hypoglycemia-a review.

Hashmi H, Khowaja A, Moheet A Front Pharmacol. 2024; 15:1349004.

PMID: 38323079 PMC: 10844401. DOI: 10.3389/fphar.2024.1349004.

Current and future therapies to treat impaired awareness of hypoglycemia.

Macon E, Devore M, Lin Y, Music M, Wooten M, McMullen C Front Pharmacol. 2023; 14:1271814.

PMID: 37942482 PMC: 10628050. DOI: 10.3389/fphar.2023.1271814.

Effects of Carvedilol on Blood Pressure, Blood Sugar, and Blood Lipids in Elderly Patients with Refractory Hypertension.

Zhang W, Deng G, Hu J, Yan R, Hu J, Fan J Comput Math Methods Med. 2022; 2022:7889024.

PMID: 35936366 PMC: 9348927. DOI: 10.1155/2022/7889024.

References

Zhu W, Czyzyk D, Paranjape S, Zhou L, Horblitt A, Szabo G . Glucose prevents the fall in ventromedial hypothalamic GABA that is required for full activation of glucose counterregulatory responses during hypoglycemia. Am J Physiol Endocrinol Metab. 2010; 298(5):E971-7. PMC: 2867375. DOI: 10.1152/ajpendo.00749.2009. View

Taborsky Jr G, Ahren B, Mundinger T, Mei Q, Havel P . Autonomic mechanism and defects in the glucagon response to insulin-induced hypoglycaemia. Diabetes Nutr Metab. 2003; 15(5):318-22; discussion 322-3. View

Chan O, Paranjape S, Czyzyk D, Horblitt A, Zhu W, Ding Y . Increased GABAergic output in the ventromedial hypothalamus contributes to impaired hypoglycemic counterregulation in diabetic rats. Diabetes. 2011; 60(5):1582-9. PMC: 3292334. DOI: 10.2337/db10-1579. View

Fan X, Ding Y, Brown S, Zhou L, Shaw M, Vella M . Hypothalamic AMP-activated protein kinase activation with AICAR amplifies counterregulatory responses to hypoglycemia in a rodent model of type 1 diabetes. Am J Physiol Regul Integr Comp Physiol. 2009; 296(6):R1702-8. PMC: 2692788. DOI: 10.1152/ajpregu.90600.2008. View

Lo Y, Lynch S, Urbanowicz R, Olson R, Ritter A, Whitehouse C . Using Machine Learning on Home Health Care Assessments to Predict Fall Risk. Stud Health Technol Inform. 2019; 264:684-688. DOI: 10.3233/SHTI190310. View

Korytkowski M, Mokan M, Veneman T, Mitrakou A, Cryer P, Gerich J . Reduced beta-adrenergic sensitivity in patients with type 1 diabetes and hypoglycemia unawareness. Diabetes Care. 1998; 21(11):1939-43. DOI: 10.2337/diacare.21.11.1939. View

McNay E, Sherwin R . From artificial cerebro-spinal fluid (aCSF) to artificial extracellular fluid (aECF): microdialysis perfusate composition effects on in vivo brain ECF glucose measurements. J Neurosci Methods. 2003; 132(1):35-43. DOI: 10.1016/j.jneumeth.2003.08.014. View

Yue J, Burdett E, Coy D, Giacca A, Efendic S, Vranic M . Somatostatin receptor type 2 antagonism improves glucagon and corticosterone counterregulatory responses to hypoglycemia in streptozotocin-induced diabetic rats. Diabetes. 2011; 61(1):197-207. PMC: 3237655. DOI: 10.2337/db11-0690. View

Cryer P . Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med. 2013; 369(4):362-72. DOI: 10.1056/NEJMra1215228. View

10.

Slucca M, Harmon J, Oseid E, Bryan J, Robertson R . ATP-sensitive K+ channel mediates the zinc switch-off signal for glucagon response during glucose deprivation. Diabetes. 2009; 59(1):128-34. PMC: 2797913. DOI: 10.2337/db09-1098. View

11.

Chan O, Paranjape S, Horblitt A, Zhu W, Sherwin R . Lactate-induced release of GABA in the ventromedial hypothalamus contributes to counterregulatory failure in recurrent hypoglycemia and diabetes. Diabetes. 2013; 62(12):4239-46. PMC: 3837027. DOI: 10.2337/db13-0770. View

12.

Paranjape S, Chan O, Zhu W, Horblitt A, McNay E, Cresswell J . Influence of insulin in the ventromedial hypothalamus on pancreatic glucagon secretion in vivo. Diabetes. 2010; 59(6):1521-7. PMC: 2874714. DOI: 10.2337/db10-0014. View

13.

Barnes M, Lawson M, Beverly J . Rate of fall in blood glucose and recurrent hypoglycemia affect glucose dynamics and noradrenergic activation in the ventromedial hypothalamus. Am J Physiol Regul Integr Comp Physiol. 2011; 301(6):R1815-20. PMC: 3233855. DOI: 10.1152/ajpregu.00171.2011. View

14.

Yue J, Riddell M, Burdett E, Coy D, Efendic S, Vranic M . Amelioration of hypoglycemia via somatostatin receptor type 2 antagonism in recurrently hypoglycemic diabetic rats. Diabetes. 2013; 62(7):2215-22. PMC: 3712070. DOI: 10.2337/db12-1523. View

15.

de Vries M, Lawson M, Beverly J . Dissociation of hypothalamic noradrenergic activity and sympathoadrenal responses to recurrent hypoglycemia. Am J Physiol Regul Integr Comp Physiol. 2004; 286(5):R910-5. DOI: 10.1152/ajpregu.00254.2002. View

16.

Cryer P . Hypoglycemia-associated autonomic failure in diabetes. Am J Physiol Endocrinol Metab. 2001; 281(6):E1115-21. DOI: 10.1152/ajpendo.2001.281.6.E1115. View

17.

. Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes. 1997; 46(2):271-86. View

18.

Bergenstal R, Polonsky K, Pons G, Jaspan J, Rubenstein A . Lack of glucagon response to hypoglycemia in type I diabetics after long-term optimal therapy with a continuous subcutaneous insulin infusion pump. Diabetes. 1983; 32(5):398-402. DOI: 10.2337/diab.32.5.398. View

19.

Szepietowska B, Zhu W, Sherwin R . β2-Adrenergic receptor agonist administration promotes counter-regulatory responses and recovery from hypoglycaemia in rats. Diabetologia. 2013; 56(11):2517-23. PMC: 3857969. DOI: 10.1007/s00125-013-3009-7. View

20.

McCrimmon R, Evans M, Jacob R, Fan X, Zhu Y, Shulman G . AICAR and phlorizin reverse the hypoglycemia-specific defect in glucagon secretion in the diabetic BB rat. Am J Physiol Endocrinol Metab. 2002; 283(5):E1076-83. DOI: 10.1152/ajpendo.00195.2002. View